Article
Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.
Oncology - 1 Jan 2011
Akie Kenji, Oizumi Satoshi, Ogura Shigeaki, Shinagawa Naofumi, Kikuchi Eiki, Fukumoto Shinichi, Harada Masao, Kinoshita Ichiro, Kojima Tetsuya, Harada Toshiyuki, Fujita Yuka, Ohsaki Yoshinobu, Dosaka-Akita Hirotoshi, Isobe Hiroshi, Nishimura Masaharu
Abstract excerpt
OBJECTIVE: Platinum-free regimens can represent an alternative for advanced non-small cell lung cancer (NSCLC) if similar efficacy is provided with better tolerability. This study evaluated the efficacy and safety of combined irinotecan and S-1 for chemotherapy-naïve advanced NSCLC. METHODS: Chemotherapy consisted of 4-week cycles of intravenous irinotecan (100 mg/m(2), days 1 and 15) and oral S-1 (80 mg/m(2),...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.